Schroder Investment Management Group Increases Stock Position in Immatics (NASDAQ:IMTX)

Schroder Investment Management Group grew its holdings in Immatics (NASDAQ:IMTX - Free Report) by 52.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 427,994 shares of the company's stock after purchasing an additional 147,547 shares during the period. Schroder Investment Management Group owned about 0.36% of Immatics worth $2,953,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Immatics in the third quarter worth $114,000. Quarry LP grew its holdings in shares of Immatics by 29.4% in the third quarter. Quarry LP now owns 11,000 shares of the company's stock worth $126,000 after acquiring an additional 2,500 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Immatics by 24.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock worth $163,000 after acquiring an additional 4,477 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Immatics in the fourth quarter worth $211,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Immatics in the third quarter worth $298,000. Institutional investors own 64.41% of the company's stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $16.67.

Immatics Trading Down 5.0 %

Shares of IMTX traded down $0.20 during midday trading on Thursday, hitting $3.84. 124,078 shares of the company's stock traded hands, compared to its average volume of 646,915. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77. The firm's fifty day moving average is $4.65 and its 200-day moving average is $6.91. The stock has a market capitalization of $466.63 million, a price-to-earnings ratio of -5.80 and a beta of 0.85.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.51. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. On average, equities research analysts anticipate that Immatics will post -0.72 EPS for the current year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.